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Abstract
Background The role of antipsychotics in influencing
mortality of patients with mental disorders is still
unexplained.
Objective The aim of this study was to determine mortality
rates of patients treated with atypical and typical antipsy-
chotics and to compare these data with the mortality rates
for the general population.
Methods The study was based on the 2008–2012 pre-
scription drug reimbursement data from the Polish National
Health Fund in Gdansk and mortality data from the death
registry. Age-standardized death rates (SDRs) and 95 %
confidence intervals (CIs) were calculated for individuals
prescribed solely atypical or typical antipsychotics, patients
prescribed both atypical and typical antipsychotics, and
patients prescribed clozapine.
Results Between 2008 and 2012, typical and/or atypical
antipsychotics and clozapine were prescribed to a total of
81,313 patients. The SDR for typical antipsychotic users
(69.6 per 1000, 95 % CI 67.64–71.56) was higher than for
those treated with both typical and atypical antipsychotics
(53.25 per 1000, 95 % CI 50.8–55.69) or clozapine (65.11
per 1000, 95 % CI 58.63–71.58). The lowest mortality was
documented in the case of patients treated exclusively with
atypical antipsychotics (SDR = 48.38 per 1000, 95 % CI,
44.78–51.98). The SDRs for patients treated with antipsy-
chotics were more than tenfold higher than the respective
SDRs for the general population in 2008, but later in 2012,
the differences dropped to threefold.
Conclusion Although the study was based on administra-
tive record linkage and therefore could not be adjusted for
potential confounders, its results suggest that mortality in
atypical antipsychotic users is lower than in typical
antipsychotic users.
Key Points for Decision Makers
The effect of antipsychotics on mortality in
schizophrenia is highly debated. A database of
refunded prescriptions created by the National
Health Fund in 2008 in Poland provided an
opportunity to monitor and analyze mortality rates in
users of typical and atypical antipsychotics.
The lowest mortality was documented in patients
treated exclusively with atypical antipsychotics
compared with users of typical drugs and clozapine
users.
Changes in disparities between the mortality of
antipsychotic users and in the general population
between 2012 and 2008 may reflect changes in
physicians’ prescribing behavior in Poland.
1 Introduction
Nearly all mental disorders are associated with increased
mortality [1]. This phenomenon is observed for all of the
main causes of death [2].
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While all-cause mortality of patients with
schizophrenia is two to threefold higher compared with
the general population, mortality as a result of natural
causes and suicide mortality are estimated to be two and
ten times higher, respectively [3, 4]. The growing gap in
survival of patients with schizophrenia and in individuals
from the general population was also documented in
recent population-based cohort studies [5]. The role of
antipsychotics in influencing the mortality of
schizophrenia patients is still unexplained [6]. Several
studies, including the landmark Clinical Antipsychotic
Trials of Intervention Effectiveness (CATIE) study,
showed limited differences between the various
antipsychotics [7, 8]. Long-term treatment with
antipsychotics is associated with lower mortality com-
pared with no antipsychotic use and the lowest mortality
was observed for clozapine [5]. Although some authors
showed that the mortality risk among the second-gen-
eration antipsychotic users is lower than in persons
treated with the first-generation antipsychotics, other
researchers did not observe this phenomenon [9, 10].
Much of the difference is attributed to the higher
prevalence of cardiovascular and metabolic disease and
also other behavioral risk factors. It is not entirely clear
how much of the underlying cardiovascular disease is
due to the metabolic side effects of medications such as
olanzapine and clozapine. The risk of QT prolongation
and subsequent arrhythmia-related events is viewed as
one of the most important safety aspects for atypical
antipsychotics [11]. Second-generation antipsychotics,
also called atypical antipsychotics, are used in many
countries including Poland in the treatment of bipolar
disease. Atypical antipsychotics are also prescribed to
the elderly to treat behavioral and psychosocial symp-
toms associated with dementia and delirium, which are
disorders associated with high mortality. Warning letters
were issued by the US Food and Drug Administration
and others about the increasing mortality associated with
the use of antipsychotics in the elderly with dementia
[12]. The role of antipsychotics in these diseases is still
unexplained. Mentally ill patients show an intrinsic
disease-related increase in medical morbidity and mor-
tality, independent of treatment. The extent to which
treatment with antipsychotics decreases or increases this
intrinsic disease-related increase in medical morbidity
and mortality remains unclear. To the best of our
knowledge, the mortality of Polish patients with mental
disorders has not been studied to date. Consequently, the
aim of this study was to determine the mortality rates of
patients from Northern Poland treated with atypical and
typical antipsychotics and to compare these data with the
mortality rates for the general population of Poland.
2 Methods
The study was based on the prescription drug reimburse-
ment data from the Pomeranian Branch of the National
Health Fund (NHF) for the period between January 1, 2008
and December 31, 2012. The NHF is a state institution that
finances healthcare benefits from contributions paid by
people insured in this organization. The NHF is responsible
for the provision of healthcare benefits for all insured
persons and their family members. According to the Law of
23 January, 2003 on the General Insurance in the National
Health Fund (Official Journal of Law 03.45.391, with later
amendments), persons covered by the general health
insurance (on a compulsory or voluntary basis) are entitled
to free healthcare services in the territory of Poland. More
than 93 % of Polish citizens are entitled to the prescription
drug and health service reimbursement in Poland.
2.1 Reimbursement Regulations
Antipsychotics are used in the treatment of schizophrenia,
psychotic disorders, and bipolar affective disorder.
According to the NHF policy, atypical antipsychotics were
reimbursed only for patients with schizophrenia (during the
whole analyzed 2008–2012 period), bipolar affective dis-
order (2010–2012), and dementia (since 2011). Typical
antipsychotics were reimbursed for individuals with a vast
array of various psychiatric conditions including not only
schizophrenia but also depression, anxiety, and psychotic
organic disorders. The restricted reimbursement policy for
atypical antipsychotics is associated with their higher cost
and the limited resources of the Polish healthcare system.
In line with the new Reimbursement Act of 2012, the
spectrum of psychiatric conditions eligible for the reim-
bursement of antipsychotics, especially atypical antipsy-
chotics, underwent further dramatic changes. The
Reimbursement Act provisions caused increased patient
charges and changed physicians’ drug-prescribing behav-
ior. Owing to a fear of being fined, physicians more often
prescribe drugs fully covered by the patient.
2.2 Study Population
We analyzed the data for all the antipsychotic prescriptions
that have been reimbursed by the NHF during a 5-year
period between 2008 and 2012. Therefore, the study pop-
ulation included all individuals who had been prescribed at
least one reimbursed antipsychotic. All the subjects were
18 years of age or older. The date of the first prescription
was considered the date of the subject’s entry into the
study. Mortality data were obtained from the Death Reg-
istry as of December 31, 2012. Data derived from the
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Pomeranian Branch of the NHF were used, as the avail-
ability of the whole nationwide data is still limited owing
to differences in informatics systems and different legal
interpretations of regulations across different NHF
branches.
2.3 Statistical Analysis
Age-standardized death rates (SDRs, with 95 % confidence
intervals) were calculated, cumulatively for the 2008–2012
period and separately for each year. Four groups of patients
were considered: (1) individuals prescribed solely atypical
antipsychotics (amisulpride, aripiprazole, quetiapine,
olanzapine, risperidone, sertindole, tiapride, and ziprasi-
done), (2) persons prescribed solely typical antipsychotics
(chlorpromazine, chlorprothixene, flupentixol, haloperidol,
levomepromazine, perazine, perphenazine, prochlorper-
azine, promazine, sulpiride, zuclopenthixol, and clo-
penthixol), (3) subjects prescribed both typical and atypical
antipsychotics, and (4) those prescribed clozapine. Cloza-
pine was analyzed separately as a specific agent used in
drug-resistant schizophrenia. Moreover, the respective
SDRs for a geographically matched population from
Pomeranian Voivodeship were calculated.
3 Results
A total of 1,095,518 prescriptions were issued for 84,881
patients during the analyzed period. The prevalence of
getting a prescription for an antipsychotic was 0.9%.
Characteristics of the 81,313 typical and/or atypical
antipsychotic and clozapine users are presented in Table 1.
The groups of patients prescribed atypical antipsychotics,
alone (n = 9767) or in combination with the typical
antipsychotics (n = 11,114), were younger and included a
higher proportion of women than the group treated solely
with typical antipsychotics (n = 56,977). Moreover,
clozapine users (n = 3455) were younger than the
remaining patients. The number of refunded prescriptions
dramatically dropped after 2008. There was only 40 % of
baseline prescriptions observed in 2009 and 25 % in 2012.
The proportion of patients who died during the analyzed
period was 21 % for typical antipsychotic users, 17.1 % for
atypical antipsychotic users, 16.1 % for atypical and typi-
cal neuroleptic users, and 16.1 % for clozapine users. The
SDRs for all the analyzed groups are shown in Table 2.
The SDR for typical antipsychotic users was higher than
for those treated with typical and atypical antipsychotics or
clozapine. Irrespective of sex, the lowest mortality was
documented in patients treated exclusively with atypical
antipsychotics.
The most evident differences in the SDRs for the
antipsychotic users and the general population was
observed in 2008 and 2009. Overall, 2008–2012 SDRs for
female and male patients from the analyzed groups are
presented in Figs. 1 and 2, and the SDRs for year 2012
separately in Figs. 3 and 4.
The difference in the SDRs for the typical and atypical
antipsychotic users was more pronounced in the case of
men than in women. During the whole 2008–2012 period,
the SDRs for the clozapine users were higher than for the
atypical antipsychotic users (Figs. 1, 2). The SDR for male
clozapine users was lower than for men treated with typical
antipsychotics (Fig. 2). Women prescribed clozapine and
those treated with conventional antipsychotics did not
differ significantly in terms of their SDRs (Fig. 1). In 2012,
the absolute differences in the SDRs for patients from
various groups were less pronounced than in 2008–2011
(Figs. 3, 4). Treatment with both atypical and typical
antipsychotics was associated with a slightly higher mor-
tality than with the atypical antipsychotics alone.








2008–2012 (n) 56,977 9767 11,114 3455
2008 (n) 24,626 3897 7659 2658
2009 (n) 10,279 1306 1368 310
2010 (n) 8507 1289 943 221
2011 (n) 7510 1480 743 171
2012 (n) 6055 1795 410 95
Age, years (mean ± SD) 57.68 ± 18.47 55.98 ± 21.74 54.04 ± 19.02 50.95 ± 18.78 \0.001
Male patients, % (n) 43.96 (25,043) 39.80 (3887) 42.32 (6410) 50.22 (1720) \0.001
Deaths, % (n) 21.02 (11,976) 17.12 (1672) 16.13 (1793) 16.15 (558) \0.001
SD standard deviation
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4 Discussion
We showed that depending on the group of antipsychotics
and the analyzed year, the SDRs for Polish patients were
three to more than tenfold higher than the respective SDRs
for the general population. However, the difference in the
mortality rates apparently decreased with time. Previous
studies dealing with the problem in question showed that
the mortality risk of schizophrenia patients is two to
threefold higher compared with individuals from the gen-
eral population [9]. We observed such a small difference
solely for 2012, when the SDR for atypical antipsychotic
users was threefold higher than the SDR for the general
population. However, up to tenfold differences in the SDRs
of antipsychotic users and the general population were
observed in 2008–2009. It is very likely that not all indi-
viduals who have been prescribed antipsychotics experi-
enced schizophrenia. Some patients eligible for treatment
with typical antipsychotics may present with somatic dis-
orders affecting mental health, or mental retardation, both
associated with an increased mortality risk. Therefore, the
relative excess in the mortality of patients who have been
prescribed antipsychotics in 2008–2009 might result from a
higher prevalence of somatic disorders in this group. This
Table 2 Age-standardized
death rates per 1000 (with 95 %
confidence intervals) for
patients treated with typical and/
or atypical antipsychotics or
clozapine and individuals from
the general population
Group Women Men Total
2008–2012
Only atypical agents 39.06 (34.79–43.33) 62.92 (56.6–69.17) 48.38 (44.78–51.98)
Atypical ? typical agents 42.82 (39.83–45.8) 68.4 (64.34–72.45) 53.25 (50.8–55.69)
Clozapine 53.5 (45.69–61.32) 79.2 (69.29–89.11) 65.11 (58.63–71.58)
Only typical agents 49.51 (46.0–52.03) 94.68 (91.65–97.71) 69.6 (67.64–71.56)
General population 5.42 (5.37–5.47) 10.12 (10.04–10.21) 7.48 (7.43–7.53)
2008
Only atypical agents 68.17 (61.25–75.1) 98.78 (88.22–109.34) 79.21 (73.31–85.11)
Atypical ? typical agents 72.45 (66.82–78.1) 102.98 (95.32–110.65) 84.33 (79.78–88.88)
Clozapine 85.01 (70.83–99.18) 113.99 (98.17–129.82) 95.57 (85.28–105.87)
Only typical agents 71.56 (67.2–75.91) 126.31 (121.21–131.4) 94.44 (91.16–97.73)
General population 5.79 (5.66–5.91) 10.77 (10.56–10.97) 7.95 (7.84–8.06)
2009
Only atypical agents 55.04 (49.77–60.31) 83.5 (74.77–92.23) 65.32 (60.57–70.08)
Atypical ? typical agents 58.66 (54.14–63.18) 92.17 (85.6–98.73) 71.45 (67.65–75.24)
Clozapine 62.99 (51.68–74.3) 97.65 (82.37–112.92) 78.07 (68.25–87.88)
Only typical agents 59.91 (55.56–64.27) 103.56 (98.77–108.35) 77.45 (74.29–80.61)
General population 5.62 (55.01–57.4) 10.56 (10.36–10.76) 7.76 (7.65–7.87)
2010
Only atypical agents 45.25 (40.66–49.85) 70.61 (63.07–78.15) 54.99 (50.81–59.16)
Atypical ? typical agents 45.73 (41.98–49.48) 73.8 (67.92–79.68) 57.18 (53.78–60.59)
Clozapine 48.17 (39.19–57.15) 70.97 (58.03–83.92) 58.57 (50.56–66.57)
Only typical agents 45.55 (42.6–48.85) 83.68 (79.33–88.04) 61.48 (58.74–64.22)
General population 5.26 (5.15–5.37) 9.96 (9.77–10.15) 7.32 (7.22–7.43)
2011
Only atypical agents 22.22 (19.14–25.3) 32.49 (27.41–37.56) 26.13 (23.43–28.83)
Atypical ? typical agents 24.42 (21.57–27.27) 37.31 (33.06–41.57) 29.51 (27.12–31.91)
Clozapine 27.67 (19.5–35.85) 36.19 (27.1–46.48) 31.08 (24.99–37.17)
Only typical agents 20.6 (18.4–22.8) 34.52 (31.36–37.69) 26.95 (24.95–28.95)
General population 5.15 (5.04–5.27) 9.57 (9.39–9.76) 7.1 (6.99–7.2)
2012
Only atypical agents 16.2 (13.77–18.62) 29.61 (24.71–34.51) 25.36 (22.46–28.27)
Atypical ? typical agents 17.41 (15.13–19.7) 30.46 (26.47–34.44) 26.89 (24.43–29.35)
Clozapine 22.29 (15.63–29) 24.81 (16.39–33.23) 25.98 (20.35–31.61)
Only typical agents 23.57 (20.15–27) 40.49 (37.17–43.82) 27.85 (25.91–29.79)
General population 5.32 (5.21–5.43) 9.86 (9.68–10.05) 7.32 (7.22–7.42)
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observation is consistent with the evidence from previous
studies analyzing the effect of physical illness on the
mortality of patients with mental disorders [13].
In turn, the relative decrease in the mortality of
antipsychotic users observed in 2012 might reflect changes
in the drug reimbursement criteria and prescription prac-
tices of Polish physicians, for example, the inclusion of less
severe cases as eligible for treatment or the reimbursement
of atypical antipsychotics solely for patients with specific
conditions. A number of physicians were sued by the NHF
in 2006–2009, and eventually were sentenced to refund the
costs of second-generation antipsychotic reimbursement
because of inconsistencies in medical documentation.
Furthermore, the Reimbursement Act of 2012 influenced
the antipsychotic prescription patterns in Poland. Owing to
the introduction of tight control mechanisms, the drugs are
reimbursed only in specified cases. Consequently, it is
likely that in 2012, atypical antipsychotics were prescribed
on-label in most cases, i.e., solely for patients with estab-
lished schizophrenia or bipolar affective disorder. There-
fore, only the data for 2012, when the SDRs for atypical
antipsychotic users were approximately threefold higher
than the SDRs for the general population, seem to be free
from a potential bias, especially taking into account that the
threefold excess in the mortality of patients with mental
disorders was also reported previously from other countries
[14]. The drop in the number of refunded prescriptions
probably reflects the shift from refunded drugs to drugs
fully covered by the patients.
The discrepancy in the risk difference between typical
and atypical neuroleptics users can be explained by chan-
neling bias. Channeling is a form of allocation bias, where
Fig. 1 Age-standardized death rates (SDRs) per 1000 with 95 %
confidence intervals for female patients from Northern Poland
prescribed typical and/or atypical antipsychotics and clozapine;
cumulated data for 2008–2012
Fig. 2 Age-standardized death rates (SDRs) per 1000 with 95 %
confidence intervals for male patients from Northern Poland pre-
scribed typical and/or atypical antipsychotics and clozapine; cumu-
lated data for 2008–2012
Fig. 3 Age-standardized death rates (SDRs) per 1000 with 95 %
confidence intervals for female patients from Northern Poland
prescribed typical and/or atypical antipsychotics and clozapine;
separate data for year 2012
Fig. 4 Age-standardized death rates (SDRs) per 1000 with 95 %
confidence intervals for male patients from Northern Poland pre-
scribed typical and/or atypical antipsychotics and clozapine; separate
data for year 2012
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drugs with similar therapeutic indications are prescribed to
groups of patients with prognostic differences [15].
Claimed advantages of a newer atypical drugs may channel
to patients with a special pre-existing morbidity, with the
consequence that disease states can be incorrectly attrib-
uted to the use of the drug. Generally, in Europe and USA,
payers do not typically dictate which antipsychotic to use,
although they may give guidance that influences the
changing pattern of prescriptions through time.
Potential causes for the excess in the mortality of Polish
patients with mental disorders include cigarette smoking,
alcohol and medication abuse, inappropriate diet, and
economic deprivation. Other postulated reasons behind the
higher mortality of subjects from this group include a
higher prevalence of concomitant cardiovascular disorders
and increased suicide risk [16].
We showed that the subjects treated with typical and
atypical antipsychotics differed significantly in terms of
their mortality rates. The results of the largest meta-anal-
ysis published to date suggest that some second-generation
antipsychotics may be more efficient than the first-gener-
ation agents, but this finding should be interpreted cau-
tiously, taking into account all potential limitations
inherent to meta-analyses [17]. A large retrospective cohort
study of elderly patients showed that the use of typical
antipsychotics is associated with a significantly higher
adjusted mortality risk [18]. The fact that the SDRs for
individuals prescribed both typical and atypical antipsy-
chotics were higher than the SDRs for patients treated
exclusively with the atypical agents can be interpreted in
terms of the greater severity of the disease in the former
group, which enforced the use of polytherapy [19].
4.1 Study Limitations
The principal limitation of this study stems from the fact
that it was based on administrative record linkage. As a
result, our analysis was not adjusted for such important
modifiers of mortality risk such as concomitant diseases,
and psychosocial, demographic, and lifestyle-related fac-
tors, and was controlled only for the age and sex of the
participants. The difficulties related to the analysis of
administrative records were discussed previously [20]. The
differences in the proportion of atypical antipsychotics
prescribed during consecutive years might reflect a pre-
scription and selection bias, namely selection by indication,
owing to a reimbursement policy or as a result of marketing
activities undertaken by a manufacturer. Prescription bias
occurs when patients with systemic diseases affecting the
brain secondarily are not prescribed atypical drugs because
patients with organic disease and exogenous psychosis are
not eligible. It is noteworthy that new indications for
treatment with atypical antipsychotics (i.e., bipolar affec-
tive disorder and dementia) emerged during the study
period. Finally, we do not know the proportion of Polish
physicians who refrained from prescribing an atypical
antipsychotic when the diagnosis was ambiguous and/or
inappropriately documented.
5 Conclusion
Polish patients eligible for treatment with antipsychotics
differed from the general population of Poland in terms of
their mortality rates. The risk of death was more than
tenfold higher than the respective risk for the general
population in 2008, but later in 2012, the differences
dropped to threefold. The lowest number of refunded pre-
scriptions was observed in 2012, possibly owing to a
change in the drug refund scheme. In individuals who were
prescribed typical antipsychotics, the mortality rate was
significantly higher than in ever users of atypical medica-
tions and people using only atypical drugs. Mortality risk in
clozapine users was also higher than in users of atypical
medications. The beneficial effect of atypical antipsychotic
use on mortality is more pronounced in men than in
women. Antipsychotics are prescribed not only to indi-
viduals with purely mental illnesses but also to persons
whose mental health is affected owing to the presence of a
somatic condition or psychosocial problem. Antipsychotic
use may be also affected by reimbursement regulations.
Consequently, the antipsychotic prescription rate should
not be considered a surrogate marker for the prevalence of
psychiatric disorders.
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